ATProto Browser

{
  "text": "The way patent protections work for drugs is clownishly silly-- it should be a simple similarity measure for compounds with collected data, but the situation in biologics is even worse, and definitely will need to be re-regulated. www.nature.com/articles/s41...",
  "$type": "app.bsky.feed.post",
  "embed": {
    "$type": "app.bsky.embed.external",
    "external": {
      "uri": "https://www.nature.com/articles/s41587-024-02549-w",
      "thumb": {
        "$type": "blob",
        "ref": {
          "$link": "bafkreigs5zhcrdsdli2ul5nclcgxqcip7pyuby7e6r5jt6xwek32dsm6x4"
        },
        "mimeType": "image/jpeg",
        "size": 689306
      },
      "title": "Redefining antibody patent protection using paratope mapping and CDR-scanning - Nature Biotechnology",
      "description": "Patent protection for therapeutic monoclonal antibodies requires a fundamental shift in strategy following Amgen v. Sanofi, which invalidated broad functional claims for antibody genera in the USA."
    }
  },
  "langs": [
    "en"
  ],
  "facets": [
    {
      "index": {
        "byteEnd": 261,
        "byteStart": 231
      },
      "features": [
        {
          "uri": "https://www.nature.com/articles/s41587-024-02549-w",
          "$type": "app.bsky.richtext.facet#link"
        }
      ]
    }
  ],
  "createdAt": "2025-02-24T18:17:28.751Z"
}